Patents by Inventor Tessa Gordon
Tessa Gordon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240108844Abstract: A humidification system can include a heater base, a humidification chamber, and a breathing circuit. A cartridge can be removably coupled to the heater base. The cartridge can include various sensors, probes, sensor wire connectors, heater wire connectors, and/or other features. The cartridge can include features configured to mate with corresponding features on the humidification chamber and the heater base. The cartridge includes a memory, such as an EEPROM, or other suitable storage device. When the cartridge is installed on the heater base, the memory is electrically connected to a processor and/or memory of the heater base. Various models of cartridges can be produced for use with different humidification chambers, breathing circuits, and/or therapies. A connector can be configured to couple an inspiratory conduit to an outlet port of the humidification chamber. The connector can provide a pneumatic connection to the outlet port and an electrical connection to the cartridge.Type: ApplicationFiled: September 20, 2023Publication date: April 4, 2024Inventors: Hamish Adrian OSBORNE, Gavin Walsh Millar, Stephen David Evans, Bruce Gordon Holyoake, James William Stanton, David Leon McCauley, Gareth Thomas McDermott, Nicholas James Michael McKenna, Myfanwy Jane Antica Norton, Adrian John Elsworth, Michael John Andresen, Jonathan Andrew George Lambert, Sandeep Singh Gurm, Tessa Hazel Paris, Joseph Nathaniel Griffiths, Ping Si, Christopher Gareth Sims, Elmo Benson Stoks, Dexter Chi Lun Cheung, Peter Alan Seekup, Po-Yen Liu, Richard Edward Lang, Paul James Tonkin, Ian Lee Wai Kwan
-
Patent number: 11376224Abstract: The present disclosure provides delivery systems for delivering FK506 locally to damaged nerve sites. Particulate FK506 incorporated into a fibrin gel, with the amount of FK506 sufficient to give an FK506 release rate over at least 14 days of at least 5 micrograms per milliliter of the treated tissue per day has been shown to remarkably improve axon regeneration. The delivery systems include particulate FK506 having sizes between about 500 microns to about 1 millimeter encapsulated in a fibrin matrix, powdered FK506 encapsulated within electrospun films, powdered FK506 encapsulated within a cellulose matrix, and a flexible film of small intestinal submucosa having a plurality of solid islands located on one side thereof, with each island containing a preselected amount of FK506 and a polyester.Type: GrantFiled: April 4, 2017Date of Patent: July 5, 2022Assignee: THE HOSPITAL FOR SICK CHILDRENInventors: Kasra Tajdaran, Gregory Borschel, Tessa Gordon
-
Publication number: 20220033517Abstract: Use of an inhibitor of the ErbB2 receptor for treatment: or repair of nerves and/or nerve tissues is provided. The inhibitor includes art antibody, in particular, a monoclonal antibody, Or example, Herceptin. A medicament for treatment or repair of nerves and/or nerve tissues can be formulated which includes an inhibitor of the ErbB2 receptor. A pharmaceutical kit may include a medicament having an inhibitor of the ErbB2 receptor and dosing instructions for administrating the medicament for treatment or repair of nerves and/or nerve tissues. Also provided are uses of an inhibitor of the ErbB2 receptor for increasing axon regeneration, preventing neuron or glial cell death, and/or stimulating Schwann cell proliferation in a nerve stump.Type: ApplicationFiled: July 2, 2021Publication date: February 3, 2022Inventors: James M. HENDRY, Eva PLACHETA, Tessa GORDON, Gregory H. BORSCHEL
-
Patent number: 11053321Abstract: Use of an inhibitor of the ErbB2 receptor for treatment or repair of nerves and/or nerve tissues is provided. The inhibitor includes an antibody, in particular, a monoclonal antibody, for example, Herceptin. A medicament for treatment or repair of nerves and/or nerve tissues can be formulated which includes an inhibitor of the ErbB2 receptor. A pharmaceutical kit may include a medicament having an inhibitor of the ErbB2 receptor and dosing instructions for administrating the medicament for treatment or repair of nerves and/or nerve tissues. Also provided are uses of an inhibitor of the ErbB2 receptor for increasing axon regeneration, preventing neuron or glial cell death, and/or stimulating Schwann cell proliferation in a nerve stump.Type: GrantFiled: June 4, 2019Date of Patent: July 6, 2021Assignee: THE HOSPITAL FOR SICK CHILDRENInventors: James M. Hendry, Eva Placheta, Tessa Gordon, Gregory H. Borschel
-
Publication number: 20190352424Abstract: Use of an inhibitor of the ErbB2 receptor for treatment or repair of nerves and/or nerve tissues is provided. The inhibitor includes an antibody, in particular, a monoclonal antibody, for example, Herceptin. A medicament for treatment or repair of nerves and/or nerve tissues can be formulated which includes an inhibitor of the ErbB2 receptor. A pharmaceutical kit may include a medicament having an inhibitor of the ErbB2 receptor and dosing instructions for administrating the medicament for treatment or repair of nerves and/or nerve tissues. Also provided are uses of an inhibitor of the ErbB2 receptor for increasing axon regeneration, preventing neuron or glial cell death, and/or stimulating Schwann cell proliferation in a nerve stump.Type: ApplicationFiled: June 4, 2019Publication date: November 21, 2019Inventors: James M. HENDRY, Eva PLACHETA, Tessa GORDON, Gregory H. BORSCHEL
-
Publication number: 20190125688Abstract: The present disclosure provides delivery systems for delivering FK506 locally to damaged nerve sites. Particulate FK506 incorporated into a fibrin gel, with the amount of FK506 sufficient to give an FK506 release rate over at least 14 days of at least 5 micrograms per milliliter of the treated tissue per day has been shown to remarkably improve axon regeneration. The delivery systems include particulate FK506 having sizes between about 500 microns to about 1 millimeter encapsulated in a fibrin matrix, powdered FK506 encapsulated within electrospun films, powdered FK506 encapsulated within a cellulose matrix, and a flexible film of small intestinal submucosa having a plurality of solid islands located on one side thereof, with each island containing a preselected amount of FK506 and a polyester.Type: ApplicationFiled: April 4, 2017Publication date: May 2, 2019Inventors: KASRA TAJDARAN, GREGORY BORSCHEL, TESSA GORDON
-
Publication number: 20170058046Abstract: Use of an inhibitor of the ErbB2 receptor for treatment or repair of nerves and/or nerve tissues is provided. The inhibitor includes an antibody, in particular, a monoclonal antibody, for example, Herceptin. A medicament for treatment or repair of nerves and/or nerve tissues can be formulated which includes an inhibitor of the ErbB2 receptor. A pharmaceutical kit may include a medicament having an inhibitor of the ErbB2 receptor and dosing instructions for administrating the medicament for treatment or repair of nerves and/or nerve tissues. Also provided are uses of an inhibitor of the ErbB2 receptor for increasing axon regeneration, preventing neuron or glial cell death, and/or stimulating Schwann cell proliferation in a nerve stump.Type: ApplicationFiled: May 4, 2015Publication date: March 2, 2017Inventors: James M. HENDRY, Eva PLACHETA, Tessa GORDON, Gregory H. BORSCHEL
-
Patent number: 6937904Abstract: Recovery from peripheral nerve and nerve plexus injuries is usually slow and incomplete because the regenerating motor axons often head erroneously toward sensory receptors rather than muscle fibers and because the target muscles atrophy while waiting for the slow process of reinnervation. Research has suggested that electrical stimulation with different waveforms and temporal patterns at different times during the regeneration process might improve the clinical outcome through various mechanisms, but a practical means to deliver such stimulation has been lacking. This invention teaches the use of miniature electrical stimulators that can be implanted alongside the injured nerve(s) at the time of surgical repair and that can be powered and controlled by transmission of radiofrequency energy from outside the body so as to provide a variety of electrical stimuli at different times during the recovery process.Type: GrantFiled: December 12, 2001Date of Patent: August 30, 2005Assignee: Alfred E. Mann Institute for Biomedical Engineering at the University of Southern CaliforniaInventors: Frances J. R. Richmond, Gerald E. Loeb, Tessa Gordon
-
Publication number: 20020120309Abstract: Recovery from peripheral nerve and nerve plexus injuries is usually slow and incomplete because the regenerating motor axons often head erroneously toward sensory receptors rather than muscle fibers and because the target muscles atrophy while waiting for the slow process of reinnervation. Research has suggested that electrical stimulation with different waveforms and temporal patterns at different times during the regeneration process might improve the clinical outcome through various mechanisms, but a practical means to deliver such stimulation has been lacking. This invention teaches the use of miniature electrical stimulators that can be implanted alongside the injured nerve(s) at the time of surgical repair and that can be powered and controlled by transmission of radiofrequency energy from outside the body so as to provide a variety of electrical stimuli at different times during the recovery process.Type: ApplicationFiled: December 12, 2001Publication date: August 29, 2002Inventors: Frances J.R. Richmond, Gerald E. Loeb, Tessa Gordon